1H-indole-2-carboxamidine | 582306-91-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1H-indole-2-carboxamidine
• 英文别名: 1H-Indole-2-carboximidamide
• CAS: 582306-91-0
• 化学式: C₉H₉N₃
• 分子量: 159.191
• InChiKey: NUNZGJKXTJMXGY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.7
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1H-indole-2-carboxamidine 、 2-[(2,4-二氯苯基)亚甲基]丙二腈 在 H+ 作用下， 生成 5-Aminomethyl-6-(2,4-dichloro-phenyl)-2-(1H-indol-2-yl)-pyrimidin-4-ylamine
  参考文献：
  名称：

  Pyridine and pyrimidine derivatives

  摘要：

  本发明提供了式（I）的化合物1，在该式中，R1、R2、R3、R4和X如规范中所定义，并且其药学上可接受的盐。这些化合物可用于治疗和/或预防与DPP IV相关的疾病，例如糖尿病，特别是非胰岛素依赖性糖尿病和糖耐量受损。

  公开号：

  US20030216382A1

文献信息

• [EN] INDOLE-2 -CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE INDOLE-2 -CARBOXAMIDINE UTILISES COMME ANTAGONISTES DU RECEPTEUR NMDA
  申请人：RICHTER GEDEON VEGYESZET

  公开号：WO2006010965A1

  公开（公告）日：2006-02-02

  The present invention relates therefore first to new indole-2-carboxamidine derivatives of formula (I) - wherein the meaning of X is hydrogen or halogen atom, C1-C4 alkyl, C1-C4 alkoxy, trifluoromethyl group, Y, V and Z independently are hydrogen or halogen atom, hydroxy, cyano, C1-C4 alkylsulfonamido optionally substituted by a halogen atom or halogen atoms, C1-C4 alkanoylamido optionally substituted by a halogen atom or halogen atoms, trifluoromethyl, trifluoromethoxy, C1-C4 alkyl, C1-C4 alkoxy group, or the neighboring V and Z groups in given case together with one or more identical or different additional hetero atom and -CH= and/or -CH2- groups can form an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably benzene, dioxolane ring, A, B and C independently are substituted carbon atom or one of them is nitrogen atom, and the salts thereof. Further objects of the invention are the processes for producing indole-2-carboxamidine derivatives of formula (I), and the pharmaceutical manufacture of medicaments containing these compounds, as well as the process of treatments with these compounds, which means administering to a mammal to be treated - including human - effective amount/amounts of indole-2-carboxamidine derivatives of formula (I) of the present invention as such or as medicament. The new indole-2-carboxamidine derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.

  本发明首先涉及新的吲哚-2-羧酰胺衍生物，其化学式为（I），其中X的含义为氢原子或卤素原子，C1-C4烷基，C1-C4烷氧基，三氟甲基基团，Y、V和Z独立地为氢原子或卤素原子，羟基，氰基，C1-C4烷基磺酰胺基可选择地被卤素原子或卤素原子取代，C1-C4烷酰胺基可选择地被卤素原子或卤素原子取代，三氟甲基，三氟甲氧基，C1-C4烷基，C1-C4烷氧基，或在特定情况下与一个或多个相同或不同的额外杂原子和-CH=和/或-CH2-基团一起形成可选择取代的4-7元杂环或杂环，优选为苯环，二氧兰环，A、B和C独立地为取代的碳原子或其中之一为氮原子，以及其盐。本发明的进一步目标是制备化学式（I）的吲哚-2-羧酰胺衍生物的工艺，以及含有这些化合物的药物的制造，以及使用这些化合物进行治疗的过程，即向待治疗的哺乳动物（包括人类）施用本发明的吲哚-2-羧酰胺衍生物的有效量/量，作为药物或本身。本发明的新吲哚-2-羧酰胺衍生物化学式（I）是NMDA受体高效选择性拮抗剂，而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
• Indole-2-carboxamidine derivatives as nmda receptor antago
  申请人：Borza Istvan

  公开号：US20090048303A1

  公开（公告）日：2009-02-19

  The present invention relates therefore first to new indole-2-carboxamidine derivatives of formula (I)—wherein the meaning of X is hydrogen or halogen atom, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl group, Y, V and Z independently are hydrogen or halogen atom, hydroxy, cyano, C 1 -C 4 alkylsulfonamido optionally substituted by a halogen atom or halogen atoms, C 1 -C 4 alkanoylamido optionally substituted by a halogen atom or halogen atoms, trifluoromethyl, trifluoromethoxy, C 1 -C 4 alkyl, C 1 -C 4 alkoxy group, or the neighboring V and Z groups in given case together with one or more identical or different additional hetero atom and —CH═ and/or —CH 2 — groups can form an optionally substituted 4-7 membered homo- or heterocyclic ring, preferably benzene, dioxolane ring, A, B and C independently are substituted carbon atom or one of them is nitrogen atom, and the salts thereof. Further objects of the invention are the processes for producing indole-2-carboxamidine derivatives of formula (I), and the pharmaceutical manufacture of medicaments containing these compounds, as well as the process of treatments with these compounds, which means administering to a mammal to be treated—including human—effective amount/amounts of indole-2-carboxamidine derivatives of formula (I) of the present invention as such or as medicament. The new indole-2-carboxamidine derivatives of formula (I) of the present invention are highly effective and selective antagonists of NMDA receptor, and moreover most of the compounds are selective antagonist of NR2B subtype of NMDA receptor.

  本发明首先涉及公式(I)的新的吲哚-2-羧酰胺衍生物，其中X的含义为氢原子或卤素原子，C1-C4烷基，C1-C4烷氧基，三氟甲基基团，Y，V和Z分别为氢原子或卤素原子，羟基，氰基，C1-C4烷基磺酰氨基，可选地被卤素原子或卤素原子取代的C1-C4烷基酰胺基，三氟甲基，三氟甲氧基，C1-C4烷氧基，C1-C4烷基，或在特定情况下，相邻的V和Z基与一个或多个相同或不同的额外杂原子和—CH═和/或—CH2—基一起可以形成一个可选地取代的4-7成员的同源或杂环，优选为苯环，二氧兰环，A，B和C分别为取代的碳原子或其中之一为氮原子，以及其盐。本发明的进一步目标是生产公式（I）的吲哚-2-羧酰胺衍生物的过程，以及包含这些化合物的药物制剂的制造，以及使用这些化合物的处理过程，即向待处理的哺乳动物（包括人类）施用本发明的吲哚-2-羧酰胺衍生物的有效量/剂量，作为药物或作为药物。本发明的新的吲哚-2-羧酰胺衍生物是高效且选择性的NMDA受体拮抗剂，而且大多数化合物是NMDA受体NR2B亚型的选择性拮抗剂。
• NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1476435A1

  公开（公告）日：2004-11-17
• INDOLE-2-CARBOXAMIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS
  申请人：Richter Gedeon Vegy Szeti Gy R Rt.

  公开号：EP1773770A1

  公开（公告）日：2007-04-18
• US6867205B2
  申请人：——

  公开号：US6867205B2

  公开（公告）日：2005-03-15